Top

Published in:

Open Access 01-04-2014 | Review

Biomarkers and acute brain injuries: interest and limits

Authors: Ségolène Mrozek, Julien Dumurgier, Giuseppe Citerio, Alexandre Mebazaa, Thomas Geeraerts

Published in: Critical Care | Issue 2/2014

Abstract

For patients presenting with acute brain injury (such as traumatic brain injury, subarachnoid haemorrhage and stroke), the diagnosis and identification of intracerebral lesions and evaluation of the severity, prognosis and treatment efficacy can be challenging. The complexity and heterogeneity of lesions after brain injury are most probably responsible for this difficulty. Patients with apparently comparable brain lesions on imaging may have different neurological outcomes or responses to therapy. In recent years, plasmatic and cerebrospinal fluid biomarkers have emerged as possible tools to distinguish between the different pathophysiological processes. This review aims to summarise the plasmatic and cerebrospinal fluid biomarkers evaluated in subarachnoid haemorrhage, traumatic brain injury and stroke, and to clarify their related interests and limits for diagnosis and prognosis. For subarachnoid haemorrhage, particular interest has been focused on the biomarkers used to predict vasospasm and cerebral ischaemia. The efficacy of biomarkers in predicting the severity and outcome of traumatic brain injury has been stressed. The very early diagnostic performance of biomarkers and their ability to discriminate ischaemic from haemorrhagic stroke were studied.

Available only for authorised users

Shinozaki K, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Abe R, Tateishi Y, Hattori N, Shimada T, Hirasawa H: S-100B and neuron-specific enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review. Crit Care 2009, 13: R121. 10.1186/cc7973PubMedCentralPubMed

Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schutt S, Fritzinger M, Horn P, Vajkoczy P, Kreisel S, Brunner J, Schmiedek P, Hennerici M: Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry 2001, 70: 534-537. 10.1136/jnnp.70.4.534PubMedCentralPubMed

Weiss N, Sanchez-Pena P, Roche S, Beaudeux JL, Colonne C, Coriat P, Puybasset L: Prognosis value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage. Anesthesiology 2006, 104: 658-666. 10.1097/00000542-200604000-00008PubMed

Fountas KN, Tasiou A, Kapsalaki EZ, Paterakis KN, Grigorian AA, Lee GP, Robinson JS Jr: Serum and cerebrospinal fluid C-reactive protein levels as predictors of vasospasm in aneurysmal subarachnoid hemorrhage, Clinical article. Neurosurg Focus 2009, 26: E22. 10.3171/2009.2.FOCUS08311PubMed

Chou SH, Feske SK, Simmons SL, Konigsberg RG, Orzell SC, Marckmann A, Bourget G, Bauer DJ, De Jager PL, Du R, Arai K, Lo EH, Ning MM: Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage. Transl Stroke Res 2011, 2: 600-607. 10.1007/s12975-011-0117-xPubMedCentralPubMed

Witkowska AM, Borawska MH, Socha K, Kochanowicz J, Mariak Z, Konopka M: TNF-alpha and sICAM-1 in intracranial aneurismal rupture. Arch Immunol Ther Exp (Warsz) 2009, 57: 137-140. 10.1007/s00005-009-0010-4

Kaynar MY, Tanriverdi T, Kafadar AM, Kacira T, Uzun H, Aydin S, Gumustas K, Dirican A, Kuday C: Detection of soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in both cerebrospinal fluid and serum of patients after aneurysmal subarachnoid hemorrhage. J Neurosurg 2004, 101: 1030-1036. 10.3171/jns.2004.101.6.1030PubMed

Kessler IM, Pacheco YG, Lozzi SP, de Araujo AS Jr, Onishi FJ, de Mello PA: Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol 2005,64(Suppl 1):S1:2-S1:5. discussion S1:5

Lewis SB, Wolper RA, Miralia L, Yang C, Shaw G: Detection of phosphorylated NF-H in the cerebrospinal fluid and blood of aneurysmal subarachnoid hemorrhage patients. J Cereb Blood Flow Metab 2008, 28: 1261-1271. 10.1038/jcbfm.2008.12PubMed

10.

Kay A, Petzold A, Kerr M, Keir G, Thompson E, Nicoll J: Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: correlation with injury severity and clinical outcome. Stroke 2003, 34: 637-642. 10.1161/01.STR.0000057579.25430.16PubMed

11.

Yarlagadda S, Rajendran P, Miss JC, Banki NM, Kopelnik A, Wu AH, Ko N, Gelb AW, Lawton MT, Smith WS, Young WL, Zaroff JG: Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage. Neurocrit Care 2006, 5: 102-107. 10.1385/NCC:5:2:102PubMed

12.

Nakagawa I, Kurokawa S, Nakase H: Hyponatremia is predictable in patients with aneurysmal subarachnoid hemorrhage – clinical significance of serum atrial natriuretic peptide. Acta Neurochir (Wien) 2010, 152: 2147-2152. 10.1007/s00701-010-0735-1

13.

McGirt MJ, Lynch JR, Blessing R, Warner DS, Friedman AH, Laskowitz DT: Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2002, 51: 1128-1134. discussion 1134–1135 10.1097/00006123-200211000-00005PubMed

14.

Fergusen S, Macdonald RL: Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2007, 60: 658-667. discussion 667PubMed

15.

Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL: Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke 2007, 38: 2315-2321. 10.1161/STROKEAHA.107.484360PubMed

16.

Liszczak TM, Varsos VG, Black PM, Kistler JP, Zervas NT: Cerebral arterial constriction after experimental subarachnoid hemorrhage is associated with blood components within the arterial wall. J Neurosurg 1983, 58: 18-26. 10.3171/jns.1983.58.1.0018PubMed

17.

Takemae T, Branson PJ, Alksne JF: Intimal proliferation of cerebral arteries after subarachnoid blood injection in pigs. J Neurosurg 1984, 61: 494-500. 10.3171/jns.1984.61.3.0494PubMed

18.

Macdonald RL, Pluta RM, Zhang JH: Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 2007, 3: 256-263.PubMed

19.

Dhar R, Diringer MN: The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage. Neurocrit Care 2008, 8: 404-412. 10.1007/s12028-008-9054-2PubMedCentralPubMed

20.

Lad SP, Hegen H, Gupta G, Deisenhammer F, Steinberg GK: Proteomic biomarker discovery in cerebrospinal fluid for cerebral vasospasm following subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 2012, 21: 30-41. 10.1016/j.jstrokecerebrovasdis.2010.04.004PubMed

21.

Fassbender K, Ries S, Schminke U, Schneider S, Hennerici M: Inflammatory cytokines in CSF in bacterial meningitis: association with altered blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry 1996, 61: 57-61. 10.1136/jnnp.61.1.57PubMedCentralPubMed

22.

Peterson JW, Kwun BD, Teramura A, Hackett JD, Morgan JA, Nishizawa S, Bun T, Zervas NT: Immunological reaction against the aging human subarachnoid erythrocyte, A model for the onset of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 1989,71(5 Pt 1):718-726.PubMed

23.

Kasuya H, Shimizu T: Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J Neurosurg 1989,71(5 Pt 1):741-746.PubMed

24.

Schoch B, Regel JP, Wichert M, Gasser T, Volbracht L, Stolke D: Analysis of intrathecal interleukin-6 as a potential predictive factor for vasospasm in subarachnoid hemorrhage. Neurosurgery 2007, 60: 828-836. discussion 828–836PubMed

25.

Sarrafzadeh A, Schlenk F, Gericke C, Vajkoczy P: Relevance of cerebral interleukin-6 after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2010, 13: 339-346. 10.1007/s12028-010-9432-4PubMed

26.

Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998, 339: 321-328. 10.1056/NEJM199807303390507PubMed

27.

Taub PR, Fields JD, Wu AH, Miss JC, Lawton MT, Smith WS, Young WL, Zaroff JG, Ko NU: Elevated BNP is associated with vasospasm-independent cerebral infarction following aneurysmal subarachnoid hemorrhage. Neurocrit Care 2011, 15: 13-18. 10.1007/s12028-011-9535-6PubMedCentralPubMed

28.

Zakynthinos E, Kiropoulos T, Gourgoulianis K, Filippatos G: Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases. Heart Lung 2008, 37: 275-285. 10.1016/j.hrtlng.2007.05.010PubMed

29.

de Bold AJ: Cardiac natriuretic peptides gene expression and secretion in inflammation. J Investig Med 2009, 57: 29-32.PubMed

30.

Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J, Schulte M, von Wild K, Scherer R: Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997, 349: 245-249. 10.1016/S0140-6736(96)08093-2PubMed

31.

Tomida M, Muraki M, Uemura K, Yamasaki K: Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. Stroke 1998, 29: 1584-1587. 10.1161/01.STR.29.8.1584PubMed

32.

Sviri GE, Shik V, Raz B, Soustiel JF: Role of brain natriuretic peptide in cerebral vasospasm. Acta Neurochir (Wien) 2003, 145: 851-860. discussion 860 10.1007/s00701-003-0101-7

33.

Wysocki SJ, Zheng MH, Smith A, Norman PE: Vascular endothelial growth factor (VEGF) expression during arterial repair in the pig. Eur J Vasc Endovasc Surg 1998, 15: 225-230. 10.1016/S1078-5884(98)80180-9PubMed

34.

Martin J: Learning from vascular remodelling. Clin Exp Allergy 2000,30(Suppl 1):33-36.PubMed

35.

Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2: 737-744. 10.1038/35036374PubMedCentralPubMed

36.

Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW: Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996, 16: 28-33.PubMed

37.

Adner M, Jansen I, Edvinsson L: Endothelin-A receptors mediate contraction in human cerebral, meningeal and temporal arteries. J Auton Nerv Syst 1994,49(Suppl):S117-S121.PubMed

38.

Suzuki K, Meguro K, Sakurai T, Saitoh Y, Takeuchi S, Nose T: Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. Surg Neurol 2000, 53: 131-135. 10.1016/S0090-3019(99)00179-2PubMed

39.

Kastner S, Oertel MF, Scharbrodt W, Krause M, Boker DK, Deinsberger W: Endothelin-1 in plasma, cisternal CSF and microdialysate following aneurysmal SAH. Acta Neurochir (Wien) 2005, 147: 1271-1279. discussion 1279 10.1007/s00701-005-0633-0

40.

Mascia L, Fedorko L, Stewart DJ, Mohamed F, TerBrugge K, Ranieri VM, Wallace MC: Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke 2001, 32: 1185-1190. 10.1161/01.STR.32.5.1185PubMed

41.

Zanier ER, Refai D, Zipfel GJ, Zoerle T, Longhi L, Esparza TJ, Spinner ML, Bateman RJ, Brody DL, Stocchetti N: Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2011, 82: 157-159. 10.1136/jnnp.2009.177667PubMedCentralPubMed

42.

Guo J, Shi Z, Yang K, Tian JH, Jiang L: Endothelin receptor antagonists for subarachnoid hemorrhage. Cochrane Database Syst Rev 2012, 9: CD008354.PubMed

43.

Sills AK Jr, Clatterbuck RE, Thompson RC, Cohen PL, Tamargo RJ: Endothelial cell expression of intercellular adhesion molecule 1 in experimental posthemorrhagic vasospasm. Neurosurgery 1997, 41: 453-460. discussion 460–461 10.1097/00006123-199708000-00025PubMed

44.

Nissen JJ, Mantle D, Gregson B, Mendelow AD: Serum concentration of adhesion molecules in patients with delayed ischaemic neurological deficit after aneurysmal subarachnoid haemorrhage: the immunoglobulin and selectin superfamilies. J Neurol Neurosurg Psychiatry 2001, 71: 329-333. 10.1136/jnnp.71.3.329PubMedCentralPubMed

45.

Oshiro EM, Hoffman PA, Dietsch GN, Watts MC, Pardoll DM, Tamargo RJ: Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats. Stroke 1997, 28: 2031-2037. discussion 2037–2038 10.1161/01.STR.28.10.2031PubMed

46.

Rothoerl RD, Schebesch KM, Kubitza M, Woertgen C, Brawanski A, Pina AL: ICAM-1 and VCAM-1 expression following aneurysmal subarachnoid hemorrhage and their possible role in the pathophysiology of subsequent ischemic deficits. Cerebrovasc Dis 2006, 22: 143-149. 10.1159/000093243PubMed

47.

Van Geel WJ, Rosengren LE, Verbeek MM: An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods 2005, 296: 179-185. 10.1016/j.jim.2004.11.015PubMed

48.

Petzold A, Shaw G: Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J Immunol Methods 2007, 319: 34-40. 10.1016/j.jim.2006.09.021PubMed

49.

Petzold A, Keir G, Kay A, Kerr M, Thompson EJ: Axonal damage and outcome in subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2006, 77: 753-759. 10.1136/jnnp.2005.085175PubMedCentralPubMed

50.

Pike BR, Flint J, Dave JR, Lu XC, Wang KK, Tortella FC, Hayes RL: Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 2004, 24: 98-106.PubMed

51.

Lewis SB, Velat GJ, Miralia L, Papa L, Aikman JM, Wolper RA, Firment CS, Liu MC, Pineda JA, Wang KK, Hayes RL: Alpha-II spectrin breakdown products in aneurysmal subarachnoid hemorrhage: a novel biomarker of proteolytic injury. J Neurosurg 2007, 107: 792-796. 10.3171/JNS-07/10/0792PubMed

52.

Donato R: S-100 proteins. Cell Calcium 1986, 7: 123-145. 10.1016/0143-4160(86)90017-5PubMed

53.

Rustandi RR, Drohat AC, Baldisseri DM, Wilder PT, Weber DJ: The Ca(2+)-dependent interaction of S100B(beta beta) with a peptide derived from p53. Biochemistry 1998, 37: 1951-1960. 10.1021/bi972701nPubMed

54.

Moritz S, Warnat J, Bele S, Graf BM, Woertgen C: The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. J Neurosurg Anesthesiol 2010, 22: 21-31. 10.1097/ANA.0b013e3181bdf50dPubMed

55.

Siman R, Giovannone N, Toraskar N, Frangos S, Stein SC, Levine JM, Kumar MA: Evidence that a panel of neurodegeneration biomarkers predicts vasospasm, infarction, and outcome in aneurysmal subarachnoid hemorrhage. PLoS One 2011, 6: e28938. 10.1371/journal.pone.0028938PubMedCentralPubMed

56.

Goyal A, Failla MD, Niyonkuru C, Amin K, Fabio A, Berger RP, Wagner AK: S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma 2013, 30: 946-957. 10.1089/neu.2012.2579PubMedCentralPubMed

57.

Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H: GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 2004, 21: 1553-1561. 10.1089/neu.2004.21.1553PubMed

58.

Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, van Geel W, de Reus H, Biert J, Verbeek MM: Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004, 62: 1303-1310. 10.1212/01.WNL.0000120550.00643.DCPubMed

59.

Guzel A, Er U, Tatli M, Aluclu U, Ozkan U, Duzenli Y, Satici O, Guzel E, Kemaloglu S, Ceviz A, Kaplan A: Serum neuron-specific enolase as a predictor of short-term outcome and its correlation with Glasgow Coma Scale in traumatic brain injury. Neurosurg Rev 2008, 31: 439-444. discussion 444–445 10.1007/s10143-008-0148-2PubMed

60.

Papa L, Akinyi L, Liu MC, Pineda JA, Tepas JJ 3rd, Oli MW, Zheng W, Robinson G, Robicsek SA, Gabrielli A, Heaton SC, Hannay HJ, Demery JA, Brophy GM, Layon J, Robertson CS, Hayes RL, Wang KK: Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 2010, 38: 138-144. 10.1097/CCM.0b013e3181b788abPubMedCentralPubMed

61.

Brophy GM, Mondello S, Papa L, Robicsek SA, Gabrielli A, Tepas J 3rd, Buki A, Robertson C, Tortella FC, Hayes RL, Wang KK: Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma 2011, 28: 861-870. 10.1089/neu.2010.1564PubMedCentralPubMed

62.

Mondello S, Akinyi L, Buki A, Robicsek S, Gabrielli A, Tepas J, Papa L, Brophy GM, Tortella F, Hayes RL, Wang KK: Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery 2012, 70: 666-675.PubMedCentralPubMed

63.

Thomas DG, Palfreyman JW, Ratcliffe JG: Serum-myelin-basic-protein assay in diagnosis and prognosis of patients with head injury. Lancet 1978, 1: 113-115.PubMed

64.

Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T: Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol 1995, 43: 267-270. discussion 270–271 10.1016/0090-3019(95)80012-6PubMed

65.

Liliang PC, Liang CL, Weng HC, Lu K, Wang KW, Chen HJ, Chuang JH: Tau proteins in serum predict outcome after severe traumatic brain injury. J Surg Res 2010, 160: 302-307. 10.1016/j.jss.2008.12.022PubMed

66.

Pineda JA, Lewis SB, Valadka AB, Papa L, Hannay HJ, Heaton SC, Demery JA, Liu MC, Aikman JM, Akle V, Brophy GM, Tepas JJ, Wang KK, Robertson CS, Hayes RL: Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma 2007, 24: 354-366. 10.1089/neu.2006.003789PubMed

67.

Mondello S, Robicsek SA, Gabrielli A, Brophy GM, Papa L, Tepas J, Robertson C, Buki A, Scharf D, Jixiang M, Akinyi L, Muller U, Wang KK, Hayes RL: alphaII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma 2010, 27: 1203-1213. 10.1089/neu.2010.1278PubMedCentralPubMed

68.

Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, Nellgard P, Rosengren L, Blennow K, Nellgard B: Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006, 67: 1600-1604. 10.1212/01.wnl.0000242732.06714.0fPubMed

69.

Zetterberg H, Smith DH, Blennow K: Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol 2013, 9: 201-210. 10.1038/nrneurol.2013.9PubMedCentralPubMed

70.

Ciccarelli R, Di Iorio P, Bruno V, Battaglia G, D'Alimonte I, D'Onofrio M, Nicoletti F, Caciagli F: Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Glia 1999, 27: 275-281. 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.0.CO;2-0PubMed

71.

Whitaker-Azmitia PM, Murphy R, Azmitia EC: Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990, 528: 155-158. 10.1016/0006-8993(90)90210-3PubMed

72.

Suzuki F, Kato K, Kato T, Ogasawara N: S-100 protein in clonal astroglioma cells is released by adrenocorticotropic hormone and corticotropin-like intermediate-lobe peptide. J Neurochem 1987, 49: 1557-1563. 10.1111/j.1471-4159.1987.tb01027.xPubMed

73.

Elting JW, de Jager AE, Teelken AW, Schaaf MJ, Maurits NM, van der Naalt J, Sibinga CT, Sulter GA, De Keyser J: Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J Neurol Sci 2000, 181: 104-110. 10.1016/S0022-510X(00)00442-1PubMed

74.

Muller K, Townend W, Biasca N, Unden J, Waterloo K, Romner B, Ingebrigtsen T: S100B serum level predicts computed tomography findings after minor head injury. J Trauma 2007, 62: 1452-1456. 10.1097/TA.0b013e318047bfaaPubMed

75.

Zongo D, Ribereau-Gayon R, Masson F, Laborey M, Contrand B, Salmi LR, Montaudon D, Beaudeux JL, Meurin A, Dousset V, Loiseau H, Lagarde E: S100-B protein as a screening tool for the early assessment of minor head injury. Ann Emerg Med 2012, 59: 209-218. 10.1016/j.annemergmed.2011.07.027PubMed

76.

Rothoerl RD, Woertgen C: High serum S100B levels for trauma patients without head injuries. Neurosurgery 2001, 49: 1490-1491. author reply 1492–1493 10.1097/00006123-200112000-00054PubMed

77.

Marangos PJ, Schmechel DE: Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci 1987, 10: 269-295. 10.1146/annurev.ne.10.030187.001413PubMed

78.

Ross SA, Cunningham RT, Johnston CF, Rowlands BJ: Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg 1996, 10: 471-476. 10.1080/02688699647104PubMed

79.

Pelinka LE, Hertz H, Mauritz W, Harada N, Jafarmadar M, Albrecht M, Redl H, Bahrami S: Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock 2005, 24: 119-123. 10.1097/01.shk.0000168876.68154.43PubMed

80.

Jackson P, Thompson RJ: The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis. J Neurol Sci 1981, 49: 429-438. 10.1016/0022-510X(81)90032-0PubMed

81.

Tongaonkar P, Chen L, Lambertson D, Ko B, Madura K: Evidence for an interaction between ubiquitin-conjugating enzymes and the 26S proteasome. Mol Cell Biol 2000, 20: 4691-4698. 10.1128/MCB.20.13.4691-4698.2000PubMedCentralPubMed

82.

Papa L, Lewis LM, Silvestri S, Falk JL, Giordano P, Brophy GM, Demery JA, Liu MC, Mo J, Akinyi L, Mondello S, Schmid K, Robertson CS, Tortella FC, Hayes RL, Wang KK: Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg 2012, 72: 335-1344.

83.

Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenstrom H: Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem 1999, 45: 138-141.PubMed

84.

Lumpkins KM, Bochicchio GV, Keledjian K, Simard JM, McCunn M, Scalea T: Glial fibrillary acidic protein is highly correlated with brain injury. J Trauma 2008, 65: 778-782. discussion 782–784 10.1097/TA.0b013e318185db2dPubMed

85.

Pelinka LE, Kroepfl A, Schmidhammer R, Krenn M, Buchinger W, Redl H, Raabe A: Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma 2004, 57: 1006-1012. 10.1097/01.TA.0000108998.48026.C3PubMed

86.

Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, Brophy GM, Demery JA, Dixit NK, Ferguson I, Liu MC, Mo J, Akinyi L, Schmid K, Mondello S, Robertson CS, Tortella FC, Hayes RL, Wang KK: Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 2012, 59: 471-483. 10.1016/j.annemergmed.2011.08.021PubMed

87.

Okonkwo DO, Yue JK, Puccio AM, Panczykowski DM, Inoue T, McMahon PJ, Sorani MD, Yuh EL, Lingsma HF, Maas AI, Valadka AB, Manley GT, Casey SS, Cheong M, Cooper SR, Dams-O'Connor K, Gordon WA, Hricik AJ, Hochberger K, Menon DK, Mukherjee P, Sinha TK, Schnyer DM, Vassar MJ, Transforming, Research Clinical Knowledge In Traumatic Brain Injury Investigators: GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study. J Neurotrauma 2013, 30: 1490-1497. 10.1089/neu.2013.2883PubMedCentralPubMed

88.

Honda M, Tsuruta R, Kaneko T, Kasaoka S, Yagi T, Todani M, Fujita M, Izumi T, Maekawa T: Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase. J Trauma 2010, 69: 104-109. 10.1097/TA.0b013e3181bbd485PubMed

89.

Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR: Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 2006, 37: 2508-2513. 10.1161/01.STR.0000242290.01174.9ePubMed

90.

Foerch C, Singer OC, Neumann-Haefelin T, Du Mesnil De Rochemont R, Steinmetz H, Sitzer M: Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005, 62: 1130-1134. 10.1001/archneur.62.7.1130PubMed

91.

Dassan P, Keir G, Brown MM: Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. Cerebrovasc Dis 2009, 27: 295-302. 10.1159/000199468PubMed

92.

Jonsson H, Johnsson P, Birch-Iensen M, Alling C, Westaby S, Blomquist S: S100B as a predictor of size and outcome of stroke after cardiac surgery. Ann Thorac Surg 2001, 71: 1433-1437. 10.1016/S0003-4975(00)02612-6PubMed

93.

Ahmad O, Wardlaw J, Whiteley WN: Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review. Cerebrovasc Dis 2012, 33: 47-54. 10.1159/000332810PubMed

94.

Hill MD, Jackowski G, Bayer N, Lawrence M, Jaeschke R: Biochemical markers in acute ischemic stroke. CMAJ 2000, 162: 1139-1140.PubMedCentralPubMed

95.

Foerch C, Otto B, Singer OC, Neumann-Haefelin T, Yan B, Berkefeld J, Steinmetz H, Sitzer M: Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004, 35: 2160-2164. 10.1161/01.STR.0000138730.03264.acPubMed

96.

Foerch C, Wunderlich MT, Dvorak F, Humpich M, Kahles T, Goertler M, Alvarez-Sabin J, Wallesch CW, Molina CA, Steinmetz H, Sitzer M, Montaner J: Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007, 38: 2491-2495. 10.1161/STROKEAHA.106.480111PubMed

97.

Kazmierski R, Michalak S, Wencel-Warot A, Nowinski WL: Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients. Neurology 2012, 79: 1677-1685. 10.1212/WNL.0b013e31826e9a83PubMed

98.

Saenger AK, Christenson RH: Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem 2010, 56: 21-33. 10.1373/clinchem.2009.133801PubMed

99.

Yoo JH, Lee SC: Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001, 158: 425-430. 10.1016/S0021-9150(01)00444-0PubMed

100.

Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, Bengtsson C, Bjorkelund C, Thelle D: Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008, 28: 961-967. 10.1161/ATVBAHA.107.156596PubMed

101.

Pikula A, Boger RH, Beiser AS, Maas R, DeCarli C, Schwedhelm E, Himali JJ, Schulze F, Au R, Kelly-Hayes M, Kase CS, Vasan RS, Wolf PA, Seshadri S: Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 2009, 40: 2959-2964. 10.1161/STROKEAHA.109.557116PubMedCentralPubMed

102.

Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR: Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997, 238: 53-56. 10.1016/S0304-3940(97)00859-8PubMed

103.

Alvarez-Sabin J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribo M, Santamarina E, Quintana M, Monasterio J, Montaner J: Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 2004, 35: 1316-1322. 10.1161/01.STR.0000126827.69286.90PubMed

104.

Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001, 32: 1759-1766. 10.1161/01.STR.32.8.1759PubMed

105.

Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J: Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001, 32: 2762-2767. 10.1161/hs1201.99512PubMed

106.

Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107: 598-603. 10.1161/01.CIR.0000046451.38849.90PubMed

107.

Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernandez-Cadenas I, Penalba A, Molina CA, Montaner J: A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 2005, 36: 1415-1420. 10.1161/01.STR.0000170641.01047.ccPubMed

108.

Gappoeva MU, Izykenova GA, Granstrem OK, Dambinova SA: Expression of NMDA neuroreceptors in experimental ischemia. Biochemistry (Mosc) 2003, 68: 696-702. 10.1023/A:1024678112357

109.

Dambinova SA, Bettermann K, Glynn T, Tews M, Olson D, Weissman JD, Sowell RL: Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke. PLoS One 2012, 7: e42362. 10.1371/journal.pone.0042362PubMedCentralPubMed

110.

Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA: Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem 2003, 49: 1752-1762. 10.1373/49.10.1752PubMed

111.

Bokesch PM, Izykenova GA, Justice JB, Easley KA, Dambinova SA: NMDA receptor antibodies predict adverse neurological outcome after cardiac surgery in high-risk patients. Stroke 2006, 37: 1432-1436. 10.1161/01.STR.0000221295.14547.c8PubMed

112.

Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ: Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000, 31: 2670-2677. 10.1161/01.STR.31.11.2670PubMed

113.

Foerch C, Curdt I, Yan B, Dvorak F, Hermans M, Berkefeld J, Raabe A, Neumann-Haefelin T, Steinmetz H, Sitzer M: Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 2006, 77: 181-184. 10.1136/jnnp.2005.074823PubMedCentralPubMed

114.

Dvorak F, Haberer I, Sitzer M, Foerch C: Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc Dis 2009, 27: 37-41. 10.1159/000172632PubMed

115.

Unden J, Strandberg K, Malm J, Campbell E, Rosengren L, Stenflo J, Norrving B, Romner B, Lindgren A, Andsberg G: Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J Neurol 2009, 256: 72-77. 10.1007/s00415-009-0054-8PubMed

116.

Ernst A, Suhr J, Kohrle J, Bergmann A: Detection of stable N-terminal protachykinin A immunoreactivity in human plasma and cerebrospinal fluid. Peptides 2008, 29: 1201-1206. 10.1016/j.peptides.2008.02.006PubMed

117.

Doehner W, von Haehling S, Suhr J, Ebner N, Schuster A, Nagel E, Melms A, Wurster T, Stellos K, Gawaz M, Bigalke B: Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. J Am Coll Cardiol 2012, 60: 346-354. 10.1016/j.jacc.2012.04.024PubMed

118.

Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, Nakamura KK, Laskowitz DT, Valkirs GE, Buechler KF: Early biomarkers of stroke. Clin Chem 2003, 49: 1733-1739. 10.1373/49.10.1733PubMed

119.

Laskowitz DT, Blessing R, Floyd J, White WD, Lynch JR: Panel of biomarkers predicts stroke. Ann N Y Acad Sci 2005, 1053: 30. 10.1196/annals.1344.051PubMed

120.

Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC: Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 2009, 40: 77-85. 10.1161/STROKEAHA.108.516377PubMed

121.

Montaner J, Mendioroz M, Ribo M, Delgado P, Quintana M, Penalba A, Chacon P, Molina C, Fernandez-Cadenas I, Rosell A, Alvarez-Sabin J: A panel of biomarkers including caspase-3 and D-dimer may differentiate acute stroke from stroke-mimicking conditions in the emergency department. J Intern Med 2011, 270: 166-174. 10.1111/j.1365-2796.2010.02329.xPubMed

122.

Doehner W: Diagnostic biomarkers in cardiovascular disease: the proteomics approach. Eur Heart J 2012, 33: 2249-2251. 10.1093/eurheartj/ehs187PubMed

Title: Biomarkers and acute brain injuries: interest and limits
Authors: Ségolène Mrozek
Julien Dumurgier
Giuseppe Citerio
Alexandre Mebazaa
Thomas Geeraerts
Publication date: 01-04-2014
Publisher: BioMed Central
Published in: Critical Care / Issue 2/2014
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc13841

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Biomarkers and acute brain injuries: interest and limits

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Do heart and respiratory rate variability improve prediction of extubation outcomes in critically ill patients?

Effect of intensive care after cardiac arrest on patient outcome: a database analysis

Elevated malondialdehyde levels in sepsis - something to 'stress' about?

The ‘availability’ bias: underappreciated but with major potential implications

The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied

A systematic review of therapeutic hypothermia for adult patients following traumatic brain injury